Clinical Trial Update: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cenicriviroc mesylate for reducing arterial inflammation in people living with HIV has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cenicriviroc mesylate (cenicriviroc)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection, Elevated Cardiovascular Risk | Phase 2 | Status: COMPLETED | Results posted: 2025-07-16